INFORMATION DISCLOSURE STATEMENT BY APPLICANT	DOCKET NO. 1662/53003	SERIAL NO 09/887,204
	APPLICANT FLESHNER-BARAK et al.	
	FILING DATE December 20, 2001	GROUP To be assigned

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	2,996,431	August 15, 1961	Barry			
	3,139,383	June 30, 1964	Neville			
	3,995,058	November 30, 1976	Hammond et al.			
	4,140,755	February 20, 1979	Sheth et al.			
	4,167,558	September 11, 1979	Sheth et al.			
	4,190,672	February 26, 1980	Fahn			
	4,434,153	February 28, 1984	Urquhart et al.			
	4,557,925	December 10, 1985	Lindahl et al.			
	4,704,285	November 3, 1987	Alderman			
	4,705,651	November 10, 1987	Staibano			
	4,721,613	January 26, 1988	Urquhart et al.			
	4,752,470	June 21, 1988	Mehta			
	4,756,911	July 12, 1988	Drost et al.			
	4,758,436	July 19, 1988	Caldwell et al.			
	4,764,380	August 16, 1988	Urquhart et al.			
	4,767,627	August 30, 1988	Caldwell et al.			
	4,853,229	August 1, 1989	Theeuwes			
	4,919,938	April 24, 1990	Lovegrove et al.			
	4,983,398	January 8, 1991	Gaylord et al.			
	5,007,790	April 16, 1991	Shell			
	5,051,262	September 24, 1991	Panoz et al.			
	5,198,229	March 30, 1993	Wong et al.			
	5,232,704	August 3, 1993	Franz et al.			
	5,780,057	July 14, 1998	Conte et al.			
	5,837,284	November 17, 1998	Mehta et al.			
	5,840,756	November 24, 1998	Cohen et al.			
	6,034,101	March 7, 2000	Gupta et al.			
	6,120,803	September 19, 2000	Wong et al.			

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	6,143,326	November 7, 2000	Möckel			
	6,207,197	March 27, 2001	Illum et al.			
	6,261,601	July 17, 2001	Talwar et al.			
	6,340,475 B2	January 22, 2001	Shell et al.			

* - If pertinent

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	H4-346919	December 2, 1992	Japan			X	
	WO 99/04764	February. 4, 1999	PCT				
	0 761 209	March 12, 1997	Europe			N/A	
	WO 98/11879	March 26, 1998	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Hwang, Sung-Joo; Park, Haesun; Park, Kinam,"Gastric Retentive Drug-Delivery Systems", Critical Reviews in Therapeutic Drug Carrier Systems , 1998, Volume 15, Issue 3, pages 243-284
		Chen, Jun; Park Kinam,"Synthesis and characterization of superporous hydrogel composites", Journal of Controlled Release 65, 2000, pages 73-82
		The United States Pharmacopeia and The National Formulary, January 1, 2000, 24/ 19, page 2235 (1999)
		Chen, Jun; Blevins, William E.; Park, Haesun; Park, Kinam,"Gastric retention properties of superporous hydrogel composites", Journal of Controlled Release 64, 2000, pages 39-51
		Thompson et al., "Efficacy of oral irinotecan against neuroblastoma xenografts," Anti-Cancer Drugs, vol. 8, 1997, Rapid Science Publishers, pages 313-322.*
		Stewart et al., "Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice," Cancer Chemother Pharmacol (1997) 40, pages 259-265.*
		Rothenberg et al., "Alternative Dosing Schedules for Irinotecan," Oncology, vol. 12, no. 8, supplement no. 6, August 1998, pages 68-71.*
		Drengler et al., "Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors," Journal of Clinical Oncology, vol. 17, no. 2, February 1999, pages 685-696.*
		Bissery et al., "Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice," Anti-Cancer Drugs, vol. 7, 1996, Rapid Science Publishers, pages 437-460.*
		John G. Kuhn, "Pharmacology of Irinotecan," Oncology, vol. 12, no. 8, supplement no. 6, August 1998, pages 39-42.*
		Choi et al., "Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice," Cancer Letters 124, 1998, pages 15-21.*
		Zamboni et al., "Altered Irinotecan and SN-38 Disposition after Intravenous and Oral Administration of Irinotecan in Mice Bearing Human Neuroblastoma Xenografts," Clinical Cancer Research, vol. 4, February 1998, pages 455-462.*
		Beaulieu et al., "Comparative Assessment of P-Glycoprotein Expression in Mammalian Tissues by Immunoblotting," IJBC, 1999, vol. 4, pages 253-268.*
		Zamboni et al., "Studies of the Efficacy and Pharmacology of Irinotecan against Human Colon Tumor Zenograft Models," Clinical Cancer Research, vol. 4, March 1998, pages 743-753.*

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Lowe et al., "p53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents," Cell, vol. 74, September 24, 1993, pages 957-967.*
		Yusuke Tanigawara, "Role of P-Glycoprotein in Drug Disposition," Therapeutic Drug Monitoring, 22: 137-140, 2000, Lippincott Williams & Williams, Inc.*
		Fisher et al., "MDR Expression in Normal Tissues," Hematology/Oncology Clinics of North America,Drug Resistance in Clinical Oncology and Hematology, Vol. 9, No. 2, April 1995, pages 319-337.*
		Hung Liang Tai, "Technology evaluation: Valspodar, Novartis AG," Current-Opinion in Molecular Therapeutics, 2000; 2/4 (459-467).*
		M.F. Fromm, "P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs," International Journal of Clinical Pharmacology and Therapeutics, Vol. 38, No. 2/2000 (69-74).*
		DeMario et al., "Oral Chemotherapy: Rationale and Future Directions," Journal of Clinical Oncology, Vol. 16, No. 7 (July), 1998: pages 2557-2567.*
		Sparreboom et al., "Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine," Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 2031-2035, March 1997 Pharmacology, pages 2031-2035.*

EXAMINER Rachel Bennett	DATE CONSIDERED 6/7/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

448695

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	DOCKET NO. 1662/53003	SERIAL NO 10/026,573
	APPLICANT FLESHNER-BARAK et al.	
	FILING DATE December 20, 2001	GROUP 1615

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
KB	5,560,933	October 1, 1966	Soon-Shiong et al.			
	5,599,534	February 4, 1997	Himmelstein et al.			
KB	5,958,443	September 28, 1999	Viegas et al.			

* - If pertinent

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
KB	WO 99/32151	July 1, 1999	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER	Rachel M. Bennett	DATE CONSIDERED	6/24/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

509683

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	DOCKET NO. 1662/53003	SERIAL NO. 10/026,573
	APPLICANT Moshe FLESHNER-BARAK et al.	
	FILING DATE December 20, 2001	GROUP 1615

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
RB	5,674,874	October 7, 1997	Hausheer et al.			
RB	6,271,278	August 7, 2001	Park et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

EXAMINER Rachel M. Bennett	DATE CONSIDERED 6/27/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.